Literature DB >> 9797869

In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine.

M A Croyle1, M Stone, G L Amidon, B J Roessler.   

Abstract

In order to identify suitable adenoviral vectors for efficient delivery of transgenic proteins and peptides to the intestine, the ability of adenovirus types 5 and 41 (an enterotropic serotype) to bind to and enter undifferentiated and differentiated enterocytes was assessed. FACS analysis showed no significant difference between the virions in their ability to bind to undifferentiated Caco-2 cells as 81.6% of the cellular population bound adenovirus 5 (Ad 5) and 79.8% bound Ad 41. Both virions were also efficiently internalized in this cell type as 99.6% of the cells took up Ad 5, while 95.9% took up Ad 41. In studies with differentiated enterocytes, probable targets for oral gene delivery but rather resistant to adenovirus-mediated gene transfer, 28.4% of the population internalized the Ad 5 vector and less than 10% bound the virus. Adenovirus 41 was efficiently internalized in differentiated enterocytes as 89.6% of the cellular population took up the virus while 37.4% bound the virus. These results were consistent with those observed in vivo in rat jejunum. Thus, molecularly engineered Ad 41-based recombinants could be highly efficient vectors for delivery of transgenic proteins to differentiated enterocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797869     DOI: 10.1038/sj.gt.3300645

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Mechanistic studies on nonviral gene delivery to the intestine using in vitro differentiated cell culture models and an in vivo rat intestinal loop.

Authors:  Sally-Ann Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

3.  Crystal structure of enteric adenovirus serotype 41 short fiber head.

Authors:  Elena Seiradake; Stephen Cusack
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

5.  Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes.

Authors:  I Kirby; R Lord; E Davison; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers.

Authors:  S Lecollinet; F Gavard; M J E Havenga; O B Spiller; A Lemckert; J Goudsmit; M Eloit; J Richardson
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

7.  Development of a method for effective amplification of human adenovirus 40.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Eric Brown; Julia Davydova; Masato Yamamoto
Journal:  Arch Virol       Date:  2010-05-21       Impact factor: 2.574

8.  A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia.

Authors:  J Zabner; M Chillon; T Grunst; T O Moninger; B L Davidson; R Gregory; D Armentano
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

10.  Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo.

Authors:  John W Schoggins; Jason G D Gall; Erik Falck-Pedersen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.